ライフサイエンスコーパス: paraneoplastic cerebellar degeneration

1 pecially lung, ovarian and breast, can cause paraneoplastic cerebellar degeneration.

2 n and may be involved in the pathogenesis of paraneoplastic cerebellar degeneration.

3 thophysiology were described 10 years ago in paraneoplastic cerebellar degeneration.

4 Twenty-five patients with paraneoplastic cerebellar degeneration (44%) had high ti

5 was the cause of death of 65% HuAb positive paraneoplastic cerebellar degeneration and 10% HuAb nega

6 A man in his 30s with paraneoplastic cerebellar degeneration and anti-Tr under

7 Here, we present a patient who developed paraneoplastic cerebellar degeneration and anti-Yo antib

8 e anti-Tr immune response is associated with paraneoplastic cerebellar degeneration and Hodgkin lymph

9 litis, 1 paraneoplastic encephalomyelitis, 1 paraneoplastic cerebellar degeneration, and 1 opsoclonus

10 rum and cerebrospinal fluid of patients with paraneoplastic cerebellar degeneration associated with c

11 rocessed HLA-A2.1 restricted epitopes of the paraneoplastic cerebellar degeneration breast/ovarian ca

12 immunomodulation did not alter the course of paraneoplastic cerebellar degeneration, but improved Lam

13 at patients with the same tumour can develop paraneoplastic cerebellar degeneration by different immu

14 patients who differed from the HuAb negative paraneoplastic cerebellar degeneration cohort, HuAb posi

15 m of 57 patients with presenting symptoms of paraneoplastic cerebellar degeneration for the presence

16 A total of nine patients (16%) from both paraneoplastic cerebellar degeneration groups developed

17 /or serum samples from 5 other patients with paraneoplastic cerebellar degeneration, HL, and anti-Tr.

18 In patients with small-cell lung cancer, paraneoplastic cerebellar degeneration may occur with or

19 and immunological developments, focusing on paraneoplastic cerebellar degeneration, opsoclonus-myocl

20 In other disorders, such as paraneoplastic cerebellar degeneration or paraneoplastic

21 erebellar degeneration and 10% HuAb negative paraneoplastic cerebellar degeneration patients (P < 0.0

22 In addition, 20% of HuAb negative paraneoplastic cerebellar degeneration patients without

23 0% of HuAb positive and 20% of HuAb negative paraneoplastic cerebellar degeneration patients, the tum

24 d in the peripheral blood of two HLA-A2.1(+) paraneoplastic cerebellar degeneration patients.

25 For example, patients with paraneoplastic cerebellar degeneration (PCD) appear to s

26 among the better described autoantibodies in paraneoplastic cerebellar degeneration (PCD) combined wi

27 Except for paraneoplastic cerebellar degeneration (PCD) in HL and d

28 Paraneoplastic cerebellar degeneration (PCD) is a disord

29 Paraneoplastic cerebellar degeneration (PCD) is believed

30 The pathogenesis of Yo-mediated paraneoplastic cerebellar degeneration (PCD) is unclear.

31 Patients with paraneoplastic cerebellar degeneration (PCD) offer the o

32 Patients with paraneoplastic cerebellar degeneration (PCD) provide an

33 era from patients with Hodgkin's disease and paraneoplastic cerebellar degeneration resulted in the i

34 Furthermore, paraneoplastic cerebellar degeneration sometimes occurs

35 bodies associated with different cancers and paraneoplastic cerebellar degeneration suggests that sev

36 Patients with paraneoplastic cerebellar degeneration who were HuAb pos